SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS
First Claim
1. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being an ECC polymer which(A) comprises a plurality of polymeric molecules which have a backbone which comprises terminal units having the formula
-Yterm-b-Cy
-
(2)where Yterm is a moiety at the end of the backbone, andb is a bond or moiety which links the Cy moiety to Yterm, andCy is a moiety which is associated with other Cy moieties to provide the CYC polymer with crystallinity;
the Cy moieties in said terminal units providing at least 50% by weight of the Cy moieties in the polymeric molecules, and(B) has a crystalline melting temperature, Tp, of at least 0°
C. and a heat of fusion, Δ
H, of at least 3 J/g which result from association of the Cy moieties, Tp and Δ
H being measured on a differential scanning calorimeter (DSC) as hereinbefore described.
7 Assignments
0 Petitions
Accused Products
Abstract
Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. For some uses, particularly the delivery of drugs, a bioerodable CYC carrier is preferably used.
147 Citations
29 Claims
-
1. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being an ECC polymer which
(A) comprises a plurality of polymeric molecules which have a backbone which comprises terminal units having the formula
-Yterm-b-Cy-
(2)where Yterm is a moiety at the end of the backbone, and b is a bond or moiety which links the Cy moiety to Yterm, and Cy is a moiety which is associated with other Cy moieties to provide the CYC polymer with crystallinity; the Cy moieties in said terminal units providing at least 50% by weight of the Cy moieties in the polymeric molecules, and (B) has a crystalline melting temperature, Tp, of at least 0°
C. and a heat of fusion, Δ
H, of at least 3 J/g which result from association of the Cy moieties, Tp and Δ
H being measured on a differential scanning calorimeter (DSC) as hereinbefore described. - View Dependent Claims (2, 4, 5, 7, 8, 9, 10, 11, 12)
-
-
3. (canceled)
-
6. (canceled)
-
13-15. -15. (canceled)
-
16. A release composition which comprises a CYC carrier and a release material associated with the CYC carrier, the CYC carrier being selected from the group consisting of CYC polymers, CYC compounds and CYC assemblies and mixtures of one or more thereof,
a CYC polymer being defined as a polymer which (A) comprises polymeric molecules having a backbone and comprising at least one moiety which (i) has the formula -b-Cy, and (ii) either (A) forms part of a repeating unit of the backbone, the repeating unit having formula (1) below
-
17. (canceled)
-
19. (canceled)
-
25. (canceled)
-
29. (canceled)
Specification